Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against aspergillus fumigatus

Cytokine

Volumn 15, Issue 2, 2001, Pages 87-95

  Gonzalez, Corina E ^e   Lyman, Caron A ^a   Lee, Sondra ^a   Del Guercio, Carla ^a   Roilides, Emmanuel ^a,b   Bacher, John ^c   Gehrt, Andreas ^a   Feuerstein, Erwin ^d   Tsokos, Maria ^a   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aspergillus; Host defense; Macrophage Colony Stimulating factor; Pulmonary

Indexed keywords

RECOMBINANT COLONY STIMULATING FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLUS FUMIGATUS; CELL ACTIVATION; CONIDIUM; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HOST RESISTANCE; INOCULATION; LUNG ALVEOLUS MACROPHAGE; LUNG ASPERGILLOSIS; LUNG INFARCTION; LUNG INJURY; NEUTROPENIA; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

ASPERGILLUS; ASPERGILLUS FUMIGATUS; ORYCTOLAGUS CUNICULUS;

EID: 0035555454     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2001.0889     Document Type: Article

References (52)

1. Patterns of infection in patients with aplastic anaemia and the emergence of Aspergillus as a major cause of death
2. Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors
3. Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases
4. Invasive pulmonary aspergillosis in patients with neoplastic diseases
5. Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia
6. In vivo effects of macrophage colony-stimulating factor on human monocyte function
7. Enhancement of human monocyte function against Candida albicans by the colony-stimulating factors (CSF): IL-3, granulocyte macrophage-CSF, and macrophage-CSF
8. Effects of parenteral human recombinant macrophage colony-stimulating factor on monocyte number, phenotype and antitumor cytotoxicity in nonhuman primates
9. Macrophage colony-stimulating factor (M-CSF) enhances the capacity of murine macrophage to secrete oxygen reduction products
10. Modulation of host defenses by cytokines: Evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts
11. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections
12. Long term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor
13. Effects of macrophage colony-stimulating factor on anti-fungal activity of mononuclear phagocytes against Aspergillus fumigatus
14. Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens
15. Protective effect of human macrophage colony-stimulating factor on fungal infection. In vivo effect of human macrophage colony-stimulating factor on systemic aspergillosis and in vitro effect on the activities of macrophages
16. In vivo and In vitro effects of macrophage colony-stimulating factor (M-CSF) on bronchoalveolar macrophages for antihistoplasmal activity
17. Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat
18. Macrophage colony-stimulating factor in murine candidiasis: Serum and tissue levels during infection and protective effect of exogenous administration
19. Protective effect of human macrophage colony-stimulating factor (hM-CSF) on fungal infection. In vitro effect of hM-CSF on systemic aspergillosis and in vitro effect of hM-CSF on macrophage activities
20. Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection
21. Fungus dose-dependent primary pulmonary aspergillosis in immunosuppressed mice
22. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: The potential role of bronchoalveolar lavage D-mannitol and galactomannan as markers of infection
23. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus: Observations in two lines of defense in vivo and in vitro with human and mouse phagocytes
24. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus
25. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages
26. Damage to hyphal forms of fungi by human leukocytes in vitro: A possible host defense mechanism in aspergillosis and mucormycosis
27. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae
28. Pathogenesis of invasive pulmonary aspergillosis during persistent granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression
29. Induction of early response genes by macrophage colony-stimulating factor in normal human monocytes
30. Induction of monocyte migration by recombinant macrophage colony-stimulating factor
31. Interaction of Aspergillus fumigatus spores with human leukocytes and serum
32. Antimicrobial proteins of murine macrophages
33. Computerized tomography of invasive pulmonary aspergillosis
34. Factors associated with fatal haemoptysis in cancer patients
35. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography: A novel non-invasive method for measuring responses to antifungal therapy
36. Enhanced killing of Candida albicans by murine macrophages treated with macrophage colony-stimulating factor: Evidence for augmented expression of mannose receptors
37. The effect of recombinant human macrophage colony stimulating factor (CSF-1) on the murine mononuclear phagocyte system in vivo
38. Growth inhibition of Mycobacterium avium complex in human alveolar macrophages by the combination of recombinant macrophage colony-stimulating factor (M-CSF) and interferon gamma
39. Effects of macrophage colony-stimulating factor on reduction of viable bacteria and survival in mice during Listeria monocytogenes infection: Characteristics of monocyte subpopulations
40. Granulocyte macrophage and macrophage colony-stimulating factors activate intramacrophage killing of Leishmania mexicana amazonensis
41. Activation of human monocyte-derived macrophages to kill Schistosoma mansoni in vitro
42. Macrophage growth factor stimulates human monocyte production of interferon, tumour necrosis factor, and colony stimulating activity
43. Increases in neutrophil counts by purified human urinary colony-stimulating factor in chronic neutropenia of childhood
44. Discordant maturation as the primary biological defect in chronic myelogenousleukaemia
45. In vivo haematological effects of recombinant human macrophage colony-stimulating factor
46. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukaemia: A double-blind controlled study
47. Use of macrophage colony-stimulating factor in the treatment of fungal infections
48. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits
49. A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT
50. Evaluation of survival data and two new rank order statistics arising in its consideration